Chikungunya Virus E2 Antibody Pair [HRP]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-49168
Key Product Details
Assay Type
Sandwich ELISA
Assay Range
78.13-5000 pg/ml (example only; lot dependent)
Sensitivity
78.13 pg/ml (example only; lot dependent)
Reactivity
Virus
Product Specifications
Sample Volume Required
100 ul
Conjugate
HRP
Kit Contents for Chikungunya Virus E2 Antibody Pair [HRP]
- Mouse Monoclonal Capture Antibody: (Catalog # NBP3-49167)
- Mouse Monoclonal Detection Antibody (HRP-conjugated): (Catalog # NBP3-49161)
- Standard
Preparation and Storage
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Storage of components varies. See protocol for specific instructions.
Background: Chikungunya Virus E2
Although analysis suggests CHIKV originated in Africa over 500 years ago, first infections weren't reported until the 1950s (1-3). CHIKV has evolved three distinct genotypes, or strains, based on location, termed West African (WA), East/Central/Southern African (ECSA), and Asian (2-3). The WA strain has been most closely associated with enzootic transmission whereas the ECSA strain contributes more to urban epidemics (2). Nonhuman primates are the primary reservoir for the viral host with transmission occurring via mosquitos biting and infecting humans (1-3). Upon acute infection, the virus replicates in cells including fibroblasts and macrophages resulting in innate immune response in infected tissues characterized by infiltrating cells like macrophages, monocytes, natural killer (NK) cells, and lymphocytes (2,3). Infection results in increased production of proinflammatory cytokines such as interferon alpha (IFN-alpha) and interleukin 6 (IL-6), chemokines, and growth factors (2,3). Physical manifestations of infection are high fever, polyarthralgia, headache, arthritis, and rash (1-3). CHIKV symptoms can be confused with other infections like those from dengue fever and Zika virus (1-3). There are no specific antivirals or vaccines for CHIKV, but rather symptoms are treated with antipyretics and non-steroidal anti-inflammatory drugs (NSAIDs) (2,3). While in vitro culture models and in vivo rodent and non-human primate models have been used to study CHIKV pathogenesis and advance our knowledge of the disease, the specific cellular mechanisms are not fully understood (3).
References
1. Vu DM, Jungkind D, Angelle Desiree LaBeaud. Chikungunya Virus. Clin Lab Med. 2017;37(2):371-382. https://doi.org/10.1016/j.cll.2017.01.008
2. Silva LA, Dermody TS. Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies. J Clin Invest. 2017;127(3):737-749. https://doi.org/10.1172/JCI84417
3. Ganesan VK, Duan B, Reid SP. Chikungunya Virus: Pathophysiology, Mechanism, and Modeling. Viruses. 2017;9(12):368. Published 2017 Dec 1. https://doi.org/10.3390/v9120368
Alternate Names
Chikungunya, E2 envelope glycoprotein, P130, Spike glycoprotein E2
Additional Chikungunya Virus E2 Products
Product Documents for Chikungunya Virus E2 Antibody Pair [HRP]
Product Specific Notices for Chikungunya Virus E2 Antibody Pair [HRP]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Antibody Pairs are guaranteed for 6 months from date of receipt.
Loading...
Loading...
Loading...
Loading...